Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03805750
Other study ID # 180414
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 22, 2019
Est. completion date November 30, 2020

Study information

Verified date October 2022
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of THC and CBD in patients with Essential Tremor.


Description:

Essential tremor (ET) is the most common neurological movement disorder, affecting up to 1% of the population and up to 5% of individuals over the age of 65. ET is characterized by often disabling tremors that occur when an individual moves. The tremors most commonly affect the hands, head, voice, and legs in order of frequency, leading to impairment in activities of daily living and morbidity. No pharmacological agent has been developed for ET, though existing agents such as propranolol and primidone are used off-label to reduce tremor amplitude. Deep brain stimulation surgery is often reserved for only individuals with the most severe tremors. Patients with ET have long reported tremor benefits with the use of cannabis, though no controlled trials have been conducted. The investigators plan to conduct the first double-blind, placebo-control clinical trial of cannabis in an oral capsule. Various validated tremor rating methods will be used to quantify tremor severity, while looking at tolerability and safety.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date November 30, 2020
Est. primary completion date September 1, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Diagnosis of ET by a Movement Disorder Neurologist - Stable dose of tremor medication for a period of at least 6 weeks prior to screening - Tremor in the arms - Tremor(s) is/are moderately severe (amplitude of at least 1cm) Exclusion Criteria: - Significant non-ET related abnormal findings on neurological exam - Tremor at rest, or other features suggestive of Parkinson disease - Diagnosis of dementia - Pregnant or nursing - Childbearing potential and unable or unwilling to use contraception during course of the trial - On medications known to interact with the study drug - Current or prior history of alcohol or substance abuse - Recent exposure to primidone (within the past 21 days) or benzodiazepines (such as Valium, Ativan or Klonopin), ketoconazole, ritonavir, clarithromycin, rifampin, carbamazepine, St. Johns Wort, digoxin or other medications known to affect your liver enzymes (within the past 7 days). - Unwilling to abstain from consuming grapefruits, grapefruit juice or grapefruit containing products. - Taking medications such as warfarin, cyclosporine, and amphotericin B that are highly protein-bound - Do not wish to take a cannabis-derived agent - Allergy or sensitivity to sorbitol, xylitol, stevia or other natural sweeteners - Allergy or sensitivity to cannabis - Used cannabis or a cannabis-derived product (such as CBD oil) within the past 4 weeks or plan to use it during this research study. - Diagnosis of a psychiatric disorder (e.g., mania, bipolar depressive disorder, schizophrenia, schizoaffective disorder, or other major psychiatric disorder) - Current or prior history of suicidal thoughts and/or behavior - Active medical problem affecting the immune system, liver, gastrointestinal tract, lungs, heart, endocrine system (such as diabetes and/or thyroid), and/or a blood clotting disorder - Current infection - Reduced kidney function (GFR <60)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CBD/THC
Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
Placebo oral capsule
Matched Placebo

Locations

Country Name City State
United States University of California San Diego La Jolla California

Sponsors (4)

Lead Sponsor Collaborator
University of California, San Diego Center for Medicinal Cannabis Research, International Essential Tremor Foundation, Tilray

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Digital Spirography The tremor mean amplitude calculated using computerized spirography to measure kinetic tremors. Day 22 (100 minutes post-dose)
Secondary Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS) The performance sub scale of the TETRAS will be used to measure tremor severity. The scale ranges from 0 to 60 points (0 being no tremor). Baseline and Day 22
Secondary Global Impression of Change The Global impression of change will be calculated based on both physician and patient report. The scale ranges from a score of 1 (very much improved) to 7 (very much worse) with a score of 4 indicating 'no change'. Day 22
Secondary Number of Participants Reporting Adverse Events Based on Common Terminology Criteria Side effects survey Days 1, 3, 6, 22
Secondary Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS) This is a scale looking at risk assessment of suicidality. The presence of any positive responses will lead to further evaluation. Day 22
Secondary Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities Electrocardiographic changes from baseline measures will trigger further evaluation. EKG's will be rated as normal/abnormal relative to the baseline EKG reading, and abnormal findings will be rated as clinically significant/not clinically significant. Day 22
Secondary Accelerometry-based Assessment of Tremor Severity The spectral power density measure of accelerometry data to measure will serve as a measure of tremor severity, comparing tremor amplitude from this digital biomarker at the time of the primary outcome to the same measure at baseline. Baseline and Day 22
See also
  Status Clinical Trial Phase
Withdrawn NCT05381688 - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Completed NCT02277106 - Evaluate SAGE-547 in Participants With Essential Tremor Phase 2
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated NCT02678429 - Atlas Predicted DBS Settings in Essential Tremor N/A
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Completed NCT02523807 - Tremor Monitoring Device N/A
Active, not recruiting NCT02255929 - Gamma Knife Radiosurgery for Treatment of Essential Tremor N/A
Completed NCT01223144 - Decision-making and Emotion Recognition in Essential Tremor N/A
Completed NCT00906412 - Ventrointermediate Nucleus (VIM DBS) and Working Memory N/A
Recruiting NCT05214222 - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT03051178 - Wearable Sensor for Responsive DBS for ET N/A
Recruiting NCT03795935 - Relief From Side Effects: Clinical Use of Electrodes With Direction N/A
Not yet recruiting NCT06036368 - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor N/A
Recruiting NCT05897775 - Coordinated Reset Deep Brain Stimulation for Essential Tremor Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Completed NCT06314139 - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study. N/A
Recruiting NCT04501133 - Sensory-specific Peripheral Stimulation for Tremor Management N/A
Active, not recruiting NCT03560622 - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy N/A
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A

External Links